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separation was 4.2, the sample  was .94, the item sepa-
ration was 3.0 and the item  was .90.
CONCLUSIONS: Our results suggest that the scale ap-
pears to measure a broad domain of psychological func-
tioning. Moreover, the scale appears to lack ceiling and
floor effects, and discriminated between inpatients, out-
patients, and non-patients, suggesting the scale has excel-
lent potential to be broadly responsive to a variety of
treatment effects.
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OBJECTIVE: Measure the impact of a PBM-adminis-
tered depression health management program based on
AHCPR guidelines on the prescribing behavior of clini-
cians using long-term antidepressant therapy.
METHOD: Doctors of patients at least 75% compliant
with antidepressant medication over the last 12 months
were identified (12/97 to 1/98) for a treatment education
intervention. Physicians (n  11,646) were mailed a one-
page summary of the AHCPR depression guidelines, a
patient-specific drug profile and diagnosis survey at the
13th month of antidepressant therapy. Non-responding
clinicians were called by trained pharmacists to secure
patient diagnosis and reinforce guidelines. Patients (n 
16,277) of the intervened-upon doctors were monitored
for antidepressant use at the 17th and 20th months (5
and 8 months after month 12, taken as baseline) follow-
ing their initial prescription. The control group (n 
36,954) was frequency-matched by drug, age, gender,
and region from a PBM prescription claims database.
RESULTS: The predominantly northeastern patient pop-
ulation was 59  13.6 years old and 70% female. With a
24% clinician response rate, 3.4% and 37.1%, respec-
tively, of patients were identified with first or recurrent
episodes of depression, and 29.7% as dysthymic or
chronic. Antidepressant usage was reduced 4.7% com-
pared to controls 5 months after baseline (p  0.001),
and 6.8% at 8 months. Among those identified, 16%
known first-episode, 12% recurrent and 10% dysthymic
depressed patients had discontinued therapy at 5 months.
At 8 months, the proportions were 14%, 15%, and 14%
respectively.
CONCLUSIONS: A PBM-administered guideline-based
depression treatment quality improvement program may
enhance clinical practice and lower the medication cost
of long-term depression therapy. While a higher propor-
tion of first-episode patients discontinued drug therapy at
5 months, the observed trend was not pronounced, possi-
bly due to clinician response bias. Subsequent analyses
will explore the program’s effect on relapse rates and
medical utilization.
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Inquiry into racial and gender differences have rarely fo-
cused on prescribing of new drug therapies.
OBJECTIVE: We examined the effect of race and gender
on the likelihood of being prescribed a new antidepres-
sant (fluoxetine versus existing antidepressants) in the
South Carolina Medicaid population.
METHODS: Patients were included in the study if they
had a primary physician or hospital diagnosis of depres-
sion (based on ICD-9-CMs) between January 1, 1988
and December 31, 1990 and if they had filled an antide-
pressant prescription within 4 months following the diag-
nosis. Selection of the study period was based on the year
fluoxetine entered the market (1987). A total of 1447 pa-
tients met the inclusion and exclusion criteria. Racial and
gender differences in prescribing patterns were deter-
mined using logistic regression, controlling for age, type
of county, provider type, Medicaid eligibility, physician
visits, and early filling of prescriptions.
RESULTS: Blacks were 30% less likely than whites
(OR  0.699; CI 0.540, 0.904, p  0.01) and males were
48% less likely than females to receive a fluoxetine pre-
scription.
CONCLUSION: Results demonstrated that there were sig-
nificant racial and gender differences in the utilization of
fluoxetine in the period immediately following its launch.
The findings should be interpreted with caution as poten-
tial confounding by disease severity, patient behavior, and
certain regional characteristics were not controlled.
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Managed care organizations are striving to seek ways to
provide cost-effective care for patients with major depres-
sion.
OBJECTIVE: The primary objective is to determine the
relationship between antidepressant utilization patterns
(treatment completion, switching, and augmentation)
and overall healthcare costs from a managed care per-
spective. The secondary objective is to investigate differ-
ences between specific antidepressants regarding these
outcomes. The inquiry is guided by the question: Which
factors contribute to overall healthcare service expendi-
tures for the treatment of depression?
METHODS: Retrospective computerized claims records
from a large managed care organization were analyzed
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(N  2379). Treatment completion is defined as receiving
at least 180 days of therapy at a minimum therapeutic
dose defined by the AHCPR guidelines. Patients were in-
cluded if they had a new ICD-9 diagnosis code for depres-
sion and were newly initiated on antidepressant therapy.
Patients were excluded if they were less than 18 years old,
had a diagnosis indicating schizophrenia or bipolar de-
pression, did not have at least 9 months of follow-up data
available, or were ineligible for coverage by the plan.
RESULTS: Total drug costs were higher in patients who
completed therapy ($704 versus $311; P  0.001); how-
ever overall healthcare costs were similar ($2672 versus
$2623, P  0.84). After controlling for confounding fac-
tors, there was a significant relationship between overall
cost and the specific antidepressant selected. Total costs
were similar for patients who switched or augmented
with a second antidepressant.
CONCLUSION: Patients with a diagnosis of depression
who complete therapy have similar overall healthcare
costs compared to those who do not. The initial antide-
pressant selected significantly contributes to overall costs.
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Antidepressants are a rapidly growing class of drugs used
to treat depression. The newer agents have been demon-
strated to improve patient outcomes and lower overall
health cost. Despite these benefits, the cost of the newer
antidepressants may be significant and may be influenced
by patterns of use. This study was undertaken to examine
three potential cost drivers associated with antidepres-
sants: persistence rate; switch rate; and concurrent use of
adjunctive antianxiety/sedative/hypnotic therapy.
OBJECTIVES: Examine the rates of persistence, switch-
ing, and concurrent use of adjunctive antianxiety/seda-
tive/hypnotic agents associated with the newer antide-
pressants and determine if there is a difference between
agents. Our objective was to determine if these differ-
ences in pattern of use add “cost” to treatment. Antide-
pressants studied included fluoxetine, paroxetine, sertra-
line, and venlafaxine.
METHODS: We performed a retrospective analysis of
medical and pharmaceutical claims data for 2,000,000
commercial HMO members for a 2-year period beginning
July 1996. Inclusion criteria for the study were: 1) diagno-
sis of depression; and 2) no antidepressant use or medical
activity related to depression for 3 months prior to admis-
sion to the study. The data were stratified into two groups
for review: non-capitated and capitated plans. Statistical
analysis was performed comparing each group.
RESULTS: There is a statistically significant difference
between some agents in the rates of switching and the use
of adjunctive medications. As switching increased, total
medical cost increased. Medical cost increased to $120
from $104 per depressed member per month at switching
rates of 29.5% and 15.3%, respectively. The variation in
the use and cost of adjunctive medications was also sta-
tistically significant between some agents. The cost ranged
from $23.71 to $2.74 for adjunctive medications per de-
pressed member per month.
CONCLUSION: When determining which antidepres-
sant drug to use, it is prudent to consider additional costs
associated with switching and adjunctive medication.
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Depression is a common, disabling and expensive psychi-
atric disorder. Management of depression has become a
heavy financial burden on both patients and society.
Pharmacotherapy can reduce the cost, but the question is
which drugs are most cost-beneficial.
OBJECTIVE: The purpose of this study is to investigate
and compare the costs and benefits of different antide-
pressants in the first year management of major depres-
sive disorder, from the perspective of a managed care
third-party payer.
METHODS: A decision tree was used to model the clini-
cal management of major depressive disorder (MDD).
Imipramine and paroxetine were chosen as examples of
two main classes of antidepressants, namely, the tricyclic
antidepressants (TCAs) and selective serotonin reuptake
inhibitors (SSRIs). A cost-benefit analysis was conducted.
The cost is the cost of the antidepressant drug treatment.
The benefit is defined as the average cost of avoided
dropout. The net benefit is the difference between the de-
fined benefit and the cost of each drug treatment.
RESULTS: Within the first year time period, the cost
of using imipramine was $81.39 and the benefit was
$169.25. For paroxetine, the cost was $261.33 and the
benefit was $201.81. The net benefit of imipramine was
$87.86 and for paroxetine, $59.52.
CONCLUSION: Based on the assumptions and parame-
ters included in this model, imipramine was found to be a
preferred choice of antidepressant in the management of
MDD during the first year compared with paroxetine.
Sensitivity analysis shows that the results are robust to
the average whole sale prices of imipramine and paroxet-
ine as well as the type of depression (“dysthymic-neu-
rotic” or “reactive”).
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SELECTIVE SEROTONIN REUPTAKE INHIBITOR 
(SSRI) UTILIZATION PATTERNS IN
PATIENTS WITH OR WITHOUT A
DEPRESSION DIAGNOSIS
